ProShare Advisors’s Fortress Biotech FBIO Stock Holding History

ProShare Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-917	Closed	-$18K	–	1909
2022 Q1	$18K	Sell	917 -167	-15%	-$4.57K	﹤0.01%	2178
2021 Q4	$41K	Buy	+1,084	New	+$48.4K	﹤0.01%	2303
2021 Q3	–	Sell	-1,239	Closed	-$66K	–	2090
2021 Q2	$66K	Buy	1,239 +48	+4%	+$2.9K	﹤0.01%	2341
2021 Q1	$63K	Buy	1,191 +204	+21%	+$11.5K	﹤0.01%	2211
2020 Q4	$47K	Buy	+987	New	+$42.7K	﹤0.01%	2049
2014 Q2	–	Sell	-1,801	Closed	-$54K	–	2494
2014 Q1	$54K	Buy	+1,801	New	+$70.2K	﹤0.01%	2714
2013 Q4	–	Sell	-1,057	Closed	-$111K	–	1510
2013 Q3	$111K	Buy	1,057 +180	+21%	+$22.1K	﹤0.01%	2391
2013 Q2	$113K	Buy	+877	New	+$129K	﹤0.01%	2213

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

ProShare Advisors's FBIO Position: Q2 2022 in Review

ProShare Advisors sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 917 shares — an estimated $18K sold.

ProShare Advisors first reported a position in FBIO in Q2 2013 and held it in 8 quarters. The position peaked at $113K in Q2 2013. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

ProShare Advisors reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 917 Fortress Biotech shares in Q2 2022, an estimated $18K.
ProShare Advisors first reported a position in Fortress Biotech in Q2 2013 and held it in 8 quarters.
ProShare Advisors's Fortress Biotech position peaked at $113K in Q2 2013.
66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.